aTyr: Positive Data from Phase 1b/2a Lung Disease Trial

 Trial met primary endpoint, ATYR1923 was safe and well-tolerated.

Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids.

Clinically meaningful improvements in forced vital capacity (FVC) of 3.3% and all sarcoidosis symptom measures, including shortness of breath, cough, and fatigue, observed in the 5.0 mg/kg treatment group.

Management to host conference call and webcast today, September 13th at 8:30am ET/5:30am PT

Conference Call and Webcast

aTyr Pharma will host a conference call and webcast to discuss the results today, September 13th at 8:30am ET/5:30am PT. Interested parties may access the call by dialing toll-free 844-358-9116 from the US, or 209-905-5951 internationally and using conference ID 1957829. Links to a live webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. A replay will be available for at least 90 days following the event.

https://finance.yahoo.com/news/atyr-pharma-announces-positive-data-113000533.html